**9. Conclusion**

As we continue to learn about COVID-19 and its cardiac consequences, widespread use of cardiac markers in routine clinical practice will increase large datasets leading to better clinical characterization, cardiac imaging, and follow up leading to a better understanding of the pathophysiological mechanisms leading to cardiomyocyte injury in COVID-19. As blood tests are routinely done on patients hospitalized with COVID-19, cardiac biomarkers are easy, cost-effective and accessible method of screening for cardiac complications of COVID-19 and determining the overall prognosis of COVID-19 patients.
